Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

689 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors.
Sootome H, Fujita H, Ito K, Ochiiwa H, Fujioka Y, Ito K, Miura A, Sagara T, Ito S, Ohsawa H, Otsuki S, Funabashi K, Yashiro M, Matsuo K, Yonekura K, Hirai H. Sootome H, et al. Among authors: fujioka y. Cancer Res. 2020 Nov 15;80(22):4986-4997. doi: 10.1158/0008-5472.CAN-19-2568. Epub 2020 Sep 24. Cancer Res. 2020. PMID: 32973082
The novel VEGF receptor/MET-targeted kinase inhibitor TAS-115 has marked in vivo antitumor properties and a favorable tolerability profile.
Fujita H, Miyadera K, Kato M, Fujioka Y, Ochiiwa H, Huang J, Ito K, Aoyagi Y, Takenaka T, Suzuki T, Ito S, Hashimoto A, Suefuji T, Egami K, Kazuno H, Suda Y, Nishio K, Yonekura K. Fujita H, et al. Among authors: fujioka y. Mol Cancer Ther. 2013 Dec;12(12):2685-96. doi: 10.1158/1535-7163.MCT-13-0459. Epub 2013 Oct 18. Mol Cancer Ther. 2013. PMID: 24140932
High Potency VEGFRs/MET/FMS Triple Blockade by TAS-115 Concomitantly Suppresses Tumor Progression and Bone Destruction in Tumor-Induced Bone Disease Model with Lung Carcinoma Cells.
Fujita H, Gomori A, Fujioka Y, Kataoka Y, Tanaka K, Hashimoto A, Suzuki T, Ito K, Haruma T, Yamamoto-Yokoi H, Harada N, Sakuragi M, Oda N, Matsuo K, Inada M, Yonekura K. Fujita H, et al. Among authors: fujioka y. PLoS One. 2016 Oct 13;11(10):e0164830. doi: 10.1371/journal.pone.0164830. eCollection 2016. PLoS One. 2016. PMID: 27736957 Free PMC article.
Stress-impaired reward pathway promotes distinct feeding behavior patterns.
Fujioka Y, Kawai K, Endo K, Ishibashi M, Iwade N, Tuerde D, Kaibuchi K, Yamashita T, Yamanaka A, Katsuno M, Watanabe H, Sobue G, Ishigaki S. Fujioka Y, et al. Front Neurosci. 2024 May 9;18:1349366. doi: 10.3389/fnins.2024.1349366. eCollection 2024. Front Neurosci. 2024. PMID: 38784098 Free PMC article.
JCS 2023 Guideline on the Primary Prevention of Coronary Artery Disease.
Fujiyoshi A, Kohsaka S, Hata J, Hara M, Kai H, Masuda D, Miyamatsu N, Nishio Y, Ogura M, Sata M, Sekiguchi K, Takeya Y, Tamura K, Wakatsuki A, Yoshida H, Fujioka Y, Fukazawa R, Hamada O, Higashiyama A, Kabayama M, Kanaoka K, Kawaguchi K, Kosaka S, Kunimura A, Miyazaki A, Nii M, Sawano M, Terauchi M, Yagi S, Akasaka T, Minamino T, Miura K, Node K; Japanese Circulation Society Joint Working Group. Fujiyoshi A, et al. Among authors: fujioka y. Circ J. 2024 Apr 25;88(5):763-842. doi: 10.1253/circj.CJ-23-0285. Epub 2024 Mar 13. Circ J. 2024. PMID: 38479862 Free article. No abstract available.
Liquid Biopsy for Glioma Using Cell-Free DNA in Cerebrospinal Fluid.
Otsuji R, Fujioka Y, Hata N, Kuga D, Hatae R, Sangatsuda Y, Nakamizo A, Mizoguchi M, Yoshimoto K. Otsuji R, et al. Among authors: fujioka y. Cancers (Basel). 2024 Feb 29;16(5):1009. doi: 10.3390/cancers16051009. Cancers (Basel). 2024. PMID: 38473369 Free PMC article. Review.
689 results